Long term use of Budesonide oral suspension improves eosinophilic esophagitis,finds study
Continuing budesonide oral suspension (BOS) numerically improved maintenance and efficacy versus withdrawal among eosinophilic esophagitis patients, suggests findings from a recent study. The reports have been published in Clinical Gastroenterology and Hepatology.
Eosinophilic esophagitis (EoE) is a chronic immunemediated disease characterized by esophageal dysfunction and eosinophils/high-power field (eos/hpf) in the esophageal mucosa.The prevalence and incidence of EoE are increasing since the last decade. Budesonide oral suspension (BOS) is a novel mucoadherent topical corticosteroid formulation with a standardized viscosity and concentration, designed specifically for the treatment of EoE.
Researchers evaluated treatment withdrawal, long-term outcomes and safety of budesonide oral suspension (BOS) 2.0 mg b.i.d. in patients with eosinophilic esophagitis who completed a 12-week induction study.
For the study design, Induction full responders (≤6 eosinophils per high-power field [eos/hpf] and ≥30% reduction in Dysphagia Symptom Questionnaire [DSQ] score) to BOS 2.0 mg b.i.d. (ORBIT1/SHP621-301/NCT02605837) were randomized to continue BOS (BOS–BOS) or withdraw to placebo (BOS–PBO) for 36 weeks (ORBIT2/SHP621-302/NCT02736409). Induction partial- and non-responders, and patients who received induction placebo, received BOS for 36 weeks.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.